Prophylactic cervical lymph node irradiation provides no benefit for patients of stage IE extranodal natural killer/T cell lymphoma, nasal type

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-8

  Wang, Liang ^a   Xia, Zhong jun ^a   Lu, Yue ^a   Zhang, Yu jing ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CHOP; EPOCH; Extranodal natural killer T cell lymphoma; Prognosis; Prophylactic cervical lymph node irradiation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DESQUAMATION; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NEUTROPENIA; NK T CELL LYMPHOMA; NOSE CAVITY; PHARYNGITIS; PRIMARY TUMOR; PROPHYLACTIC CERVICAL NODE IRRADIATION; PRURITUS; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; SALIVARY GLAND DISEASE; SKIN PIGMENTATION; SKIN TOXICITY; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; AGED; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPH NODE; LYMPHATIC METASTASIS; LYMPHOMA, EXTRANODAL NK-T-CELL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIATION RESPONSE; RADIOTHERAPY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY;

EID: 84919905649     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0320-1     Document Type: Article

References (15)

1. Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, et al. Whole blood Epstein–Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2009;50(5):757–63.
2. Li YX, Liu QF, Fang H, Qi SN, Wang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009;15(8):2905–12.
3. Li CC, Tien HF, Tang JL, Yao M, Chen YC, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/Tcell or T-cell lymphoma. Cancer. 2004;100:366–75.
4. Huang MJ, Jiang Y, Liu WP, Li ZP, Li M, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70(1):166–74.
5. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 2012;96(5):617–23.
6. Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83:795–9.
7. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–6.
8. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, et al. First-line combination of gemcitabine, oxaliplatin, and l-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119:348–55.
9. Liang W, Wei-da W, Zhong-jun X, Yu-jing Z, Jin X, Yue L. Combination of gemcitabine, l-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol. 2014;31:860.
10. Li YX, Wang H, Jin J, Wang WH, Liu QF, et al. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1809–15.
11. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 285–8.
12. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931–7.
13. Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54–63.
14. Wang Z-Y, Li Y-X, Wang W-H, Jin J, Wang H, et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood. 2009;114:4771–6.
15. Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009;100:2242–8.